ReviewFrontiers in genetics2014
Induction of protective immune responses against schistosomiasis using functionally active cysteine peptidases.
Review in Frontiers in genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 45 citations in OpenAlex.
- Mechanistic insights intoJournal of advanced veterinary and animal research · 2025Article
- Schistosoma japonicum cathepsin L1: A potential target for anti-schistosomiasis strategies.PLoS neglected tropical diseases · 2025Article
- Approaches of Inducing Tolerance to Murine Schistosomiasis mansoni applying Biomphalaria and Bulinus Proteins.Acta parasitologica · 2025Article
- Evaluation of the prophylactic and therapeutic efficacies of mucus and tissue nucleoproteins extracted fromJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024Article
- Comparative membrane proteomic analysis of Tritrichomonas foetus isolates.Scientific reports · 2024Article
- Schistosoma mansoni vaccine candidates identified by unbiased phage display screening in self-cured rhesus macaques.NPJ vaccines · 2024Article
- Advances in new target molecules against schistosomiasis: A comprehensive discussion of physiological structure and nutrient intake.PLoS pathogens · 2023Review
- Antigenic epitope targets of rhesus macaques self-curing fromFrontiers in immunology · 2023Article
- A comprehensive and critical overview of schistosomiasis vaccine candidates.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2021Review
- Ginger (Zingiber Officinale)-derived nanoparticles in Schistosoma mansoni infected mice: Hepatoprotective and enhancer of etiological treatment.PLoS neglected tropical diseases · 2021Article
- Article
- In vivo assessment of the antischistosomal activity of curcumin loaded nanoparticles versus praziquantel in the treatment of Schistosoma mansoni.Scientific reports · 2020Article
- Arachidonic Acid Is a Safe and Efficacious Schistosomicide, and an Endoschistosomicide in Natural and Experimental Infections, and Cysteine Peptidase Vaccinated Hosts.Frontiers in immunology · 2020Review
- Schistosoma japonicum cathepsin B as potential diagnostic antigen for Asian zoonotic schistosomiasis.Parasitology research · 2019Article
- Role of T lymphocytes and papain enzymatic activity in the protection induced by the cysteine protease againstJournal of advanced research · 2019Article
- A secreted schistosome cathepsin B1 cysteine protease and acute schistosome infection induce a transient T helper 17 response.PLoS neglected tropical diseases · 2019Article
- Physiological functions and pathogenic potential of uric acid: A review.Journal of advanced research · 2017Review
- Protective immune responses against Schistosoma mansoni infection by immunization with functionally active gut-derived cysteine peptidases alone and in combination with glyceraldehyde 3-phosphate dehydrogenase.PLoS neglected tropical diseases · 2017Article
- Development of a schistosomiasis vaccine.Expert review of vaccines · 2016Review
- Definitive host influences the proteomic profile of excretory/secretory products of the trematode Echinostoma caproni.Parasites & vectors · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Each year schistosomiasis afflicts up to 600 million people in 74 tropical and sub-tropical countries, predominantly in the developing world. Yet we depend on a single drug, praziquantel, for its treatment and control. There is no vaccine available but one is urgently needed especially since praziquantel-resistant parasites are likely to emerge at some time in the future. The disease is caused by several worm species of the genus Schistosoma. These express several classes of papain-like cysteine peptidases, cathepsins B and L, in various tissues but particularly in their gastrodermis where they employ them as digestive enzymes. We have shown that sub-cutaneous injection of recombinant and functionally active Schistosoma mansoni cathepsin B1 (SmCB1), or a cathepsin L from a related parasite Fasciola hepatica (FhCL1), elicits highly significant protection (up to 73%) against an experimental challenge worm infection in murine models of schistosomiasis. The immune modulating properties of this subcutaneous injection can boost protection levels (up to 83%) when combined with other S. mansoni vaccine candidates, glyceraldehyde 3-phosphate dehydrogenase (SG3PDH) and peroxiredoxin (PRX-MAP). Here, we discuss these data in the context of the parasite's biology and development, and provide putative mechanism by which the native-like cysteine peptidase induce protective immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.